0
Lung Cancer: Lung Cancer IV |

Chromosomal Imbalances Detected by Array CGH From Thirty Chinese Non-Smoker Adenocarcinomas of the Lung FREE TO VIEW

Yue Gu, PhD; Shibo Li, PhD; Shucheng Hua, PhD; Xianfu Wang; Wenfu Li; Yunpeng Shi
Author and Funding Information

The First Hospital of Jilin University, Changchun, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A321. doi:10.1016/j.chest.2016.02.334
Text Size: A A A
Published online

SESSION TITLE: Lung Cancer IV

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Identifying the normal variants of chromosome alterations in order to generate biomarkers for early stage lung cancer may help patients receive a timely diagnosis and therapies.

METHODS: In this pilot study, we collected 30 tumor samples from non-smoking patients who were diagnosed with lung adenocarcinoma in clinical phase IA-IIB and underwent lobectomies. A total of 23 female patients with a mean age of 57.4 years old, and 8 male patients, with a mean age of 62.8 years old, comprised the participants in this cohort. The DNA was isolated from their tumor tissue and array comparative genomic hybridization (array CGH) was performed using Agilent’s array platform Sureprint 2x400K.

RESULTS: Approximately 81% of the samples contained a 5p region duplication and 77% of the samples contained a gain of 7p. Duplication of the long arm of chromosome 8 (61%), deletion of the short arm of chromosome 8 (52%), deletion of the short arm of chromosome 9 (41%), duplication of the long arm of chromosome 14 (48%) and duplication of short arm of 16 (48%) were also detected.

CONCLUSIONS: Compared to previous published studies, these findings had unique patterns. These differences may explain why adenocarcinoma development in a non-smoker has a different initiation, progression and prognosis compared to the adenocarcinoma development in a smoker.

CLINICAL IMPLICATIONS: The treatment for lung adenocarcinoma has made great development during the past decade especially in genetic target therapy. If we can discover target genes from these identified regions, it will enlarge the spectra of therapy and provide patients with more options.

DISCLOSURE: Yue Gu: Employee: galaries The following authors have nothing to disclose: Shibo Li, Shucheng Hua, Xianfu Wang, Wenfu Li, Yunpeng Shi

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543